Latest BioNTech News & Updates

See the latest news and media coverage for BioNTech. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioNTech

Biotechnology company developing immunotherapies and vaccines

biontech.com

Headquarters: Mainz, Germany
Founded year: 2008
Company type: Private company
Number of employees: 1,000–5,500
Industry: Pharmaceuticals

Last updated Today

Latest news about BioNTech

In short: BioNTech transitioned to a new CEO, accelerated its oncology pivot through major acquisitions, and managed declining COVID-19 revenues.

Company announcements

Yesterday BioNTech

BioNTech presents new lung cancer pipeline data at WCLC

The company showcases investigational bispecific immunomodulators and antibody-drug conjugates alongside five Phase III trials during the September Seoul event.

August 4 BioNTech

BioNTech reports its second quarter 2026 earnings and strategy

The organization cites expanding trial pipelines, strategic alliances, and fiscal stability while planning executive succession and achieving multi-product diversification by 2030.

August 3 BioNTech

BioNTech appoints Guido Oelkers as new CEO

He joins from Sobi to drive growth toward a multi-product strategy by 2030, bringing extensive pharmaceutical leadership experience.

May 18 BioNTech

BioNTech strengthens governance for future growth

Shareholders expanded the Supervisory Board to eight members, elected new and re-elected existing directors, and appointed Helmut Jeggle as Chairman.

Media coverage

Yesterday Ad hoc news

BioNTech's Seoul Data Drop Arrives at an Awkward Moment for the Stock

The sector-wide euphoria that lifted BioNTech to roughly $113 in New York proved short-lived. Moderna's own stock gave back ...

Yesterday Yahoo Finance

Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips

A historic one-session rally in a cancer vaccine stock is already unwinding, and Wall Street...

Yesterday Kapitalmarktexperten

BioNTech stock: BNT111 program halted at the end of 2025

BioNTech stock falls by 1.8 percent after Moderna rally. Analysts see little transferability of the competitor's success to their own pipeline.

August 19 Markets Insider

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator...

Never miss news about BioNTech

Track BioNTech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioNTech competitors & trending companies

Browse news for competitors to BioNTech and other trending companies.